Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non –small cell lung cancer in China
Source: Health Economics Review - Category: International Medicine & Public Health Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | China Health | Economics | International Medicine & Public Health | Lung Cancer